Fresenius SE & Co KGaA/ DE0005785604 /
1/8/2025 5:16:34 PM | Chg. +0.28 | Volume | Bid1/3/2025 | Ask12/17/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
34.57EUR | +0.82% | 995 Turnover: 34,183.57 |
-Bid Size: - | -Ask Size: - | 19.38 bill.EUR | - | - |
GlobeNewswire
4/24/2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
4/23/2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2/23/2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil